 The FDA has lifted the clinical hold on Spero Therapeutics Incs NASDAQ: SPRO Phase 2 trial of SPR720 for nontuberculous mycobacterial NTM disease. The SPR720 program was placed on a clinical hold by the FDA following a review of data from a non-human primate NHP toxicology study in which mortalities with inconclusive causality to treatment were observed. 